Note 11 - Stock and Employee Benefit Plans 1 (Tables)
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2024 |
Dec. 31, 2023 |
| Notes Tables |
|
|
| Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] |
|
| Expected volatility |
|
|
80.14% |
- |
81.01 |
% |
| Risk-free interest |
|
|
4.05% |
- |
4.08 |
% |
| Expected term (years) |
|
|
5.4 |
- |
6.0 |
|
| Expected dividend yield |
|
|
|
|
— |
|
|
| Share-Based Payment Arrangement, Option, Activity [Table Text Block] |
| |
|
Common |
|
|
Weighted |
|
|
Weighted |
|
| |
|
Shares |
|
|
Average |
|
|
Average |
|
| |
|
Underlying |
|
|
Exercise |
|
|
Remaining |
|
| |
|
Stock |
|
|
Price per |
|
|
Contractual |
|
| |
|
Options |
|
|
Share |
|
|
Life (Years) |
|
| Outstanding at December 31, 2023 |
|
|
1,581,041 |
|
|
$ |
2.72 |
|
|
|
7.3 |
|
| Granted |
|
|
568,097 |
|
|
|
2.33 |
|
|
|
|
|
| Exercised |
|
|
— |
|
|
|
|
|
|
|
|
|
| Forfeited / Cancelled |
|
|
— |
|
|
|
|
|
|
|
|
|
| Outstanding at September 30, 2024 |
|
|
2,149,138 |
|
|
$ |
2.62 |
|
|
|
7.4 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Exercisable at September 30, 2024 |
|
|
1,287,990 |
|
|
$ |
2.61 |
|
|
|
6.2 |
|
|
| |
|
Common |
|
|
Weighted |
|
|
Weighted |
|
| |
|
Shares |
|
|
Average |
|
|
Average |
|
| |
|
Underlying |
|
|
Exercise |
|
|
Remaining |
|
| |
|
Stock |
|
|
Price per |
|
|
Contractual |
|
| |
|
Options |
|
|
Share |
|
|
Life (Years) |
|
| Outstanding at January 1, 2023 |
|
|
1,024,628 |
|
|
$ |
2.53 |
|
|
|
7.1 |
|
| Granted |
|
|
608,388 |
|
|
|
3.03 |
|
|
|
|
|
| Exercised |
|
|
— |
|
|
|
|
|
|
|
|
|
| Forfeited / Cancelled |
|
|
(51,975 |
) |
|
|
2.64 |
|
|
|
|
|
| Outstanding at December 31, 2023 |
|
|
1,581,041 |
|
|
$ |
2.72 |
|
|
|
7.3 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Exercisable at December 31, 2023 |
|
|
1,009,011 |
|
|
$ |
2.56 |
|
|
|
6.5 |
|
|
| Pieris Pharmaceuticals, Inc. [Member] |
|
|
| Notes Tables |
|
|
| Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] |
|
| |
|
Years Ended December 31, |
|
| |
|
2023 |
|
|
2022 |
|
| Risk free interest rate |
|
|
3.33% - 4.11 |
% |
|
|
1.43% - 3.39 |
% |
| Expected term (in years) |
|
|
5.5 - 5.73 |
|
|
|
5.5 - 5.73 |
|
| Dividend yield |
|
|
— |
|
|
|
— |
|
| Expected volatility |
|
|
79.5% - 98.6 |
% |
|
|
79.9% - 81.1 |
% |
|
| Share-Based Payment Arrangement, Option, Activity [Table Text Block] |
|
| |
|
|
|
|
|
|
|
|
|
Weighted- |
|
|
|
|
|
| |
|
|
|
|
|
Weighted- |
|
|
Average |
|
|
Aggregate |
|
| |
|
|
|
|
|
Average |
|
|
Remaining |
|
|
Intrinsic |
|
| |
|
Number of |
|
|
Exercise |
|
|
Contractual |
|
|
Value |
|
| |
|
Options |
|
|
Price |
|
|
Life (in years) |
|
|
(in thousands) |
|
| Outstanding, December 31, 2022 |
|
|
165,849 |
|
|
$ |
256.93 |
|
|
|
|
|
|
$ |
— |
|
| Granted |
|
|
46,677 |
|
|
|
97.34 |
|
|
|
|
|
|
|
— |
|
| Canceled/Forfeited |
|
|
34,345 |
|
|
|
208.95 |
|
|
|
|
|
|
|
— |
|
| Outstanding, December 31, 2023 |
|
|
178,181 |
|
|
$ |
224.37 |
|
|
|
5.90 |
|
|
$ |
— |
|
| Vested or expected to vest, December 31, 2023 |
|
|
178,181 |
|
|
$ |
224.37 |
|
|
|
5.90 |
|
|
$ |
— |
|
| Exercisable, December 31, 2023 |
|
|
126,179 |
|
|
$ |
257.26 |
|
|
|
4.75 |
|
|
$ |
— |
|
| |
|
|
|
|
|
|
|
|
|
Weighted- |
|
|
|
|
|
| |
|
|
|
|
|
Weighted- |
|
|
Average |
|
|
Aggregate |
|
| |
|
|
|
|
|
Average |
|
|
Remaining |
|
|
Intrinsic |
|
| |
|
Number of |
|
|
Exercise |
|
|
Contractual |
|
|
Value |
|
| |
|
Options |
|
|
Price |
|
|
Life (in years) |
|
|
(in thousands) |
|
| Outstanding, December 31, 2022 |
|
|
3,750 |
|
|
$ |
372.00 |
|
|
|
|
|
|
$ |
— |
|
| Granted |
|
|
— |
|
|
$ |
— |
|
|
|
|
|
|
$ |
— |
|
| Canceled/Forfeited |
|
|
— |
|
|
$ |
— |
|
|
|
|
|
|
$ |
— |
|
| Outstanding, December 31, 2023 |
|
|
3,750 |
|
|
$ |
372.00 |
|
|
|
5.67 |
|
|
$ |
— |
|
| Vested or expected to vest, December 31, 2023 |
|
|
3,750 |
|
|
$ |
372.00 |
|
|
|
5.67 |
|
|
$ |
— |
|
| Exercisable, December 31, 2023 |
|
|
3,750 |
|
|
$ |
372.00 |
|
|
|
5.67 |
|
|
$ |
— |
|
|
| Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] |
|
| |
|
Years Ended December 31, |
|
| |
|
2023 |
|
|
2022 |
|
| Research and development |
|
$ |
1,190 |
|
|
$ |
1,905 |
|
| General and administrative |
|
|
2,159 |
|
|
|
2,497 |
|
| Total stock-based compensation |
|
$ |
3,349 |
|
|
$ |
4,402 |
|
|